Seagen (SGEN) Stock Price, News & Analysis

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings or view top-rated stocks.

2 brokers have issued 12 month price targets for Seagen's stock. Their SGEN share price targets range from $229.00 to $229.00. On average, they expect the company's stock price to reach $229.00 in the next year. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.

Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.33. The biotechnology company had revenue of $648.65 million for the quarter, compared to analyst estimates of $635.10 million. Seagen had a negative trailing twelve-month return on equity of 28.06% and a negative net margin of 32.61%. The company's revenue for the quarter was up 27.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.03) EPS.

ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Invesco US Large Cap Core ESG ETF (IVLC) and Global X Guru Index ETF (GURU).B.A.D. Etf (BAD).

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).